Leadership
Pipeline
Pipeline Overview
Ciprocopan (NXP100)
NXP200
NXP900
Clinical Trials
Publications
Investors & News
Investor Relations Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts
Contact
Careers
Email Alerts
Leadership
Pipeline
Pipeline Overview
Ciprocopan (NXP100)
NXP200
NXP900
Clinical Trials
Publications
Investors & News
Investor Relations Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts
Contact
Careers
Email Alerts
Contact Us
Disclaimer
Email Alerts
Governance Documents
Home
Investor Relations
Leadership
Ciprocopan (NXP100): Complement Factor B Inhibitor
NXP200: Paradox Breaker BRAF Inhibitor
NXP900: SRC/YES1 Kinase Inhibitor
Pipeline
Events & Presentations
Press Releases
Privacy Policy
Publications
SEC Filings
Stock Quote
Terms of Use
Clinical Trials
Careers
Clinical Trials
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
Learn More
Study of NXP900 with Osimertinib in EGFR+ Lung Cancer
Learn More
